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Cell and gene therapies (CGTs) are examples of future therapeutics that can be used to cure or
alleviate the symptoms of disease, by repairing damaged tissue or reprogramming defective genetic
information. However, despite the recent advancements in clinical trial outcomes, the path to wide-
scale adoption of CGTs remains challenging, such that the emergence of a “blockbuster” therapy
has so far proved elusive. Manufacturing solutions for these therapies require the application of
scalable and replicable cell manufacturing techniques, which differ markedly from the existing
pharmaceutical incumbent. Attempts to adopt this pharmaceutical model for CGT manufacture
have largely proved unsuccessful. The most significant challenges facing CGT manufacturing are
process analytical testing and quality control. These procedures would greatly benefit from
improved sensory technologies that allow direct measurement of critical quality attributes, such as
pH, oxygen, lactate and glucose. In turn, this would make manufacturing more robust, replicable
and standardized. In this review, the present-day state and prospects of CGT manufacturing are dis-
cussed. In particular, the authors highlight the role of fluorescent optical sensors, focusing on their
strengths and weaknesses, for CGT manufacture. The review concludes by discussing how the inte-
gration of CGT manufacture and fluorescent optical sensors could augment future bioprocessing
approaches. VC 2017 Author(s). All article content, except where otherwise noted, is licensed under
a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1116/1.5013335
I. INTRODUCTION
The last four decades have seen enormous strides in our
ability to effectively culture mammalian cells, which is an
essential requirement for the development of innovative bio-
technology.1 Cell culture is now the established method for
producing proteins, as it permits the production of large,
functionally modified and glycosylated macromolecules.2 In
addition, cell culture has also become essential for the syn-
thesis of viral vectors for gene therapies.3 Application of
these important cell and gene therapies (CGTs) has required
significant advancement in both manufacturing capacity and
sensory bioprocessing technology.4,5
While this capacity has proved exceptionally capable for
large-scale manufacture of pharmaceuticals and biologics,
future CGTs and tissue engineered therapies (TETs) are sig-
nificantly more challenging to manufacture. This is because
unlike traditional biotechnology products, manufactured by
and purified from bacteria and yeast, CGTs and TETs are
dependent on the preliminary production of complex biologi-
cal machinery, in the form of biological materials and distinct
cells lines.6 As a result, this produces challenges in determin-
ing the complexities that can arise from seemingly innocuous
changes in the culture process, as well as downstream purifi-
cation of specific cell populations. For this reason, it is diffi-
cult to achieve consistent cellular products with only the
insights provided by existing sensory technologies, as they
lack the sensitivity to detect key process parameters for effi-
cient and reproducible CGT manufacture. Therefore, the effi-
cient manufacture of CGTs will require a paradigm shift in
both manufacturing and sensory bioprocessing technologies
to become commercially viable.
A. Emerging cell and gene therapy manufacturing
paradigms
Cell culture has progressed since its early beginnings as a
tool to drive in vitro understanding in the field of biology.7
The first commercial therapeutic application of cells was as
viral hosts.8 This permitted viruses to replicate in a nonhu-
man host, which in turn could be used to manufacture inacti-
vated or weakened viruses for vaccine production.9 The next
notable step was the development of cell lines.9 These work-
horse cells share some basic biological attributes with cancer-
ous cells, which rapidly and continually divide, making them
excellent for producing large amounts of identical cells rap-
idly. Adoption of Chinese hamster ovary cells in suspension
took this a step further, such that mammalian cells could be
manufactured using the tried and tested methods of routine
microbial culture.9 Editing of cellular genetic makeup also
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allowed for the optimization of subcellular machinery to pro-
mote stable and efficient biologic medicine production.8
Following the success of cell-derived biotechnology prod-
ucts, methods to create replacement cells or tissues for cellu-
lar therapy have been ongoing. The development of a
blockbuster technology that can revolutionize the field, by
acting as a template to model subsequent regenerative medi-
cine based therapeutics, is still absent from the field.
In order to account for the different cell types and pro-
duction requirements, commercial scale cell culture can
take a number of forms. Commercial cell culture includes
both suspension and surfaces adherent methodologies,
which are highlighted in Fig. 1. While small-scale culture of
cells is appropriate for in vitro studies, it is not suitable for
mass production of biotechnology products for clinical
use.10 Therefore, for large scale production, highly efficient
bioreactors, of up to 20 000 litres, have been developed.11
Adherent cells, which require a surface to attach and
develop, are more challenging for scale up. This is due to the
barriers presented by the removal of cells from surfaces and
downstream purification and processing.10 An interim
solution, which has permitted limited scale-up of adherent
cell cultures has been through the application of roller bottles
and disk propagators.9 However, a major breakthrough for
adherent cell scale-up applications was the use of fibers or
microcarriers as attachment surfaces.14
Fiber and microcarrier reactors can provide very large
surface areas for cells to attach and grow.10 Microcarriers
are especially promising, as surface area increases can be
readily achieved through the addition of more microcarriers
to the system.15 Furthermore, porous microcarriers permit
further increases in surface area.11 As the bioreactor
increases in size, it has the potential to become much more
productive. However, as size increases and culture densities
are transformed, the culture environment must be
optimized.11
In order to determine the optimal environment and process-
ing of CGT cultures, a large degree of online sensory informa-
tion is required. This is because mammalian cells continually
require effective gas exchange and a regular replenishment of
a highly complex culture media with specific nutrient levels.
Therefore, as the volume of the bioreactors increase the need
for sensory input also increases, as they are prone to the devel-
opment of dead-spots, which are regions with suboptimal gas
and media perfusion.16 Examples of critical quality attributes
(CQAs) that would benefit from sensors and enhance bioreac-
tor performance include: small molecules and ions (pH, oxy-
gen, and carbon dioxide), metabolites (glucose, lactate, and
ammonia), and large macromolecules (enzymes, growth fac-
tors, and cytokines).17–19
B. Importance of measurement and sensors in
bioprocessing
Quantification of essential molecules and ions has under-
pinned our knowledge of biological processes.20 The pur-
pose of sensors is to specifically detect analytes in their
surroundings, transduce a signal to a detector, which is then
quantified and interpreted as a measurement. Therefore, the
importance of sensory technologies for understanding bio-
logical processes and how they contribute to cell function
cannot be understated.21 An ideal sensor should be noninva-
sive, so that it does not perturb the system or generate mea-
surement artifacts, highly sensitive and selective to the
analyte of interest, whilst providing high spatial and tempo-
ral resolution (Fig. 2).22
In order to establish enhanced bioprocessing control meth-
ods, it is an absolute necessity to have suitable monitoring
(offline and online) for the culture environment.23 Offline
monitoring is conducted by extracting samples from the cul-
ture environment, which are taken to analytical equipment for
examination. This allows for a greater range of measurements
to be performed that cannot be conducted in situ. However,
the validity of these measurements is limited if the samples
are liable to degradation, when removed from their immediate
surroundings and if the measurement itself is influenced
through interaction with external parameters (e.g., oxygen
levels15,24). Conversely, online monitoring allows real-time
FIG. 1. Schematic diagrams of scalable bioreactor platforms. Stirred tank
reactors (Ref. 12) and rocking reactors (Ref. 13) are both examples of sus-
pension culture systems where the product is grown in a constantly agitated
environment. Conversely, the hollow fiber reactors have a static perfused
bed of porous fibers that allow for very high surface areas. The stirred tank
reactor, when compared to the other two culture methods, permits the great-
est scope for large scale up applications.
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quantification of analytes of interest.17 This will yield live
information during bioprocessing, which will be essential for
the early detection of deviations from method parameters and
enable implementation of countermeasures.
C. The current state-of-art of sensory technology
Early bioprocessing was far removed from the scientifi-
cally informed engineered approaches we have today.
Fermentation processes were more akin to an art form, con-
trolled by skilled operators visually inspecting cultures.25
Since that time, bioprocessing has advanced significantly,
particularly on the back of high powered computing, auto-
mation and advanced sensory systems.25
Measurement systems developed for industrial scale
bioprocessing of bacteria or yeasts are insufficient for pro-
viding the level of characterization required for effective
control of complex cellular manufacturing environments.4,5
This is because, traditionally these measurement systems
were dependent on electrochemical sensors, which were lim-
ited by a narrow temperature window of operation, were sub-
ject to measurement inaccuracies, due to interfering gasses,
and had short lifetimes, as they were gradually degraded
through use.25–27
Mass spectrometry yields information rich datasets when
utilized to optimize bioprocessing.28 This technique has made
its way into routine use in production processes and has been
a major addition to the CGT research and development,
despite the high initial costs of setup.25 The wealth of data
provided by this technique has facilitated the bioprocessing of
the existing generation of biologics immensely and a similar
advance in monitoring technology could augment CGT
manufacturing.
More recently optical sensors have been widely applied
to commercial bioreactor platforms, due to their high sensi-
tivity and specificity for analytes of interest.29–31 For exam-
ple optical systems have been used to determine optical
density, cell number and gas composition32 as well as
quantifying biochemical parameters, such as pH, oxygen,
and carbon dioxide.33
II. ADVANCED FLUORESCENT OPTICAL SENSORS
Governments, pharmaceutical companies and universities
annually invest large sums of money into the development
of new technologies to measure biological systems both at
the large and small scale.34,35
The development of fluorescent optical sensors is an
exciting field of research involving highly multidisciplinary
teams.36 Existing probes are diverse in their formulation,
with measurement applications ranging from the characteri-
zation of small molecules and ions to large macromolecules.
Due to their noninvasive nature and relatively high sensitiv-
ity and specificity fluorescence based optical sensors, such as
fiber optics, free fluorophores and fluorescent nanosensors
are examples of excellent measurement technologies for
characterizing biological environments.37
A. Fiber optic sensors
Fiber optic sensors usually comprise of a transparent
core enveloped by a protective coating.38 Light used for
excitation is totally internally reflected to a fluorophore-
based sensor at the tip of the optode. In turn, this sensor
reports the external stimulus as a signal back to a spectro-
scopic detector at a different wavelngth. The protective coat
surrounding the optode prevents unwanted loss of fluoro-
phore in biological systems, which could reduce sensitivity
or generate measurement artifacts. Coupled with established
detection systems, such as fluorescence and confocal
microscopy, correctly calibrated pulled optical fibers can
characterize analyte concentrations through changes in fluo-
rescence. This was effectively demonstrated for glucose
oxidase by Portaccio et al., who performed temporal glu-
cose measurements with an optical fiber, coupled to a fluo-
rescence spectrophotometer.39
FIG. 2. Desirable sensor characteristics.
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The major drawback of utilizing fiber optic sensors for cel-
lular measurements is the substantial damage that can be
caused when fiber optic tips are inserted into fragile biological
structures as well as the limitations associated with point-to-
point measurements. Cellular damage can be caused by the
initial puncture force and the volume occupied by the fiber
optic tip within the cell. Both can cause perturbations in cell
function, which inadvertently changes the system being exam-
ined. Therefore, to minimize the cellular perturbations, tip
dimensions of less than 50 nm diameter have been achieved
by laser heated optical fiber pulling.40 Furthermore, operators
develop a high level of skill to ensure the insertion does not
cause excessive damage when probes are positioned in deli-
cate structures such as subcellular microenvironments.41
The point-to-point measurements made by fiber optics
probes are unable to fully characterize large volumes in tech-
nologies such as bioreactors. This is because bioreactors are
continually evolving and developing regions of distinct bio-
chemical heterogeneity for which fiber optic based sensors
are unable to characterize, which can be referred to as mea-
surement dark zones. Therefore, to overcome this limitation
fluorophore and fluorescent nanosensors can be distributed
throughout a volume to determine its properties.
B. Free fluorophores
Fluorescent molecules that are able to freely move within
a system have been widely implemented for both quantitative
and qualitative imaging. Individual molecules of fluorophores
usually produce a fast and bright response. In addition, due to
their relatively low molecular weight (typically<1000 MW)
these molecules impose minimal physical perturbations when
successfully delivered to cells.42 However, there are
drawbacks with fluorescent molecules as signal transducers.
Cellular delivery can be challenging as molecules may per-
meate the cell membrane unassisted.43 Furthermore, there
could be interference from cellular components that generate
measurement artifacts44 and subsequently nonratiometric
measurements.45 Finally, isolated molecules of fluorescent
sensors spread throughout a biological system may bleach to
a level below detectable background limits more rapidly than
packed clusters of sensors in one location (Fig. 3).46
The delivery of free fluorophores to living cells is chal-
lenging primarily because of the natural obstruction provided
by the cell membrane. Certain fluorophores readily traverse
cell membranes. However, this ease of transport across cell
membranes is also their weakness, allowing them to readily
leach out or into other subcellular spaces. This was demon-
strated by Rink et al. who found 6-carboxyfluorescein leached
by up to 40% after 10 min when applied to lymphocytes.47
To overcome challenges of the cellular delivery of fluoro-
phores, they can be chemically modified or alternatively pur-
chased with chemical moieties, e.g., acetoxymethyl and
acetate esters, to enhance their cellular uptake.48 It is impor-
tant to note, it is not always possible to chemically modify
all fluorophores this way without affecting the sensory capa-
bilities. Furthermore, the fluorophores which are success-
fully taken up by cells are able to freely interact with cellular
components. Free interaction with biological components
can also hinder sensing capabilities and unintentionally bind
to cellular material such as proteins49 or initiate cellular tox-
icity.50 These interactions can also quench fluorescence or
present as measurement artifacts.
When fluorophores are successfully delivered to a cell it
is challenging to ascertain uptake levels of the fluorophore.
FIG. 3. Free fluorophore and polymeric nanosensors trapped in a polymer matrix demonstrating bleaching over time. In brief, 50 nm polyacrylamide nanopar-
ticles containing the dye 5-carboxytetramethylrhodamine were encapsulated in a translucent polymer matrix. These matrices were imaged on a Zeiss Elyra
super resolution fluorescence microscope, with stochastic optical reconstruction microscopy. Images were recorded for 15 min continuously. Scale bar¼ 5lm.
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This is a critical drawback for making quantitative measure-
ments with free fluorophores. To overcome this drawback,
ratiometric fluorophores can be used, which emit a second-
ary reference signal at a different wavelength, independent
of analyte concentration. By obtaining a ratio of indicator
signal to reference signal, accurate ratiometric measurements
can be made, which are independent of fluorophore concen-
tration, fluctuations in excitation energy, as well as detector
sensitivity and light scattering.38 Thus, ratiometric fluoro-
phores are well suited at making accurate quantitative meas-
urements. However, very few fluorophores are intrinsically
ratiometric,48 yet it is possible to chemically modify fluoro-
phores to convey ratiometric properties. This can however
be at the expense of the sensory capacity of the fluorophore,
which could be affected by the modification process. It is
important to note the simultaneous delivery of a secondary
reference fluorophore, in addition to the analyte sensitive flu-
orophore will not produce ratiometric measurements. This is
because the observer cannot be certain if the secondary fluo-
rophore occupies the same spatial coordinate as the indicator
fluorophore, in identical ratios when distributed at a range of
locations throughout a cell.
C. Polymeric fluorescent nanosensors
Polymeric fluorescent nanosensors are probes comprising
of an inert matrix with nanometer-sized dimensions that
selectively respond to specific analytes in their surroundings
to transduce fluorescence signals to a detector.51 Due to their
small size, high signal-to-noise ratio and versatile inert
matrix, fluorescent nanosensors can be thought of as power-
ful tools that represent an advance in optical sensor based
technologies. Fluorescent nanosensors combine the benefits
of both fiber optic sensors and free fluorophores, while over-
coming some of their inherent weaknesses.
The key differentiator of fluorescent nanosensors that sets
them apart from both fiber optic sensors and free fluoro-
phores is the inert, chemically versatile nanosensor matrix,
which serves to both enhance sensing capabilities and aug-
ment cellular delivery (Fig. 4). Sensors can be modified with
key chemical entities to modify their interaction with exter-
nal environments. Each modification can elicit a range of
actions. These include enhancement of sensing capabilities
through the attachment of different analyte sensitive fluoro-
phores or extended circulation lifetime through polyethylene
glycol coating and subsequent reduction of affinity to pro-
teins and cell membranes.52 Internally, sensors consist of a
ratiometric reference dye, which facilitates both tracking of
the sensor and ratiometric measurements.53 Additionally,
there must be a sensor dye which reacts to the analyte of
interest.
Fluorescent nanosensors are composed of a porous bio-
friendly polymeric matrix, such as polyacrylamide,54 silica
sol-gel,52 polystyrene derivatives,55 and poly(methyl methac-
rylate),56 and usually present with dimensions that are less
than pulled optical fibers, but greater than free fluorophores.
The large surface area of the nanosensor permits a small vol-
ume of sensing elements to interact with a large number of
analytes. Due to the versatility of the nanosensor matrix, a
large number of sensing elements can be incorporated into a
very small volume, such that ratiometric nanosensors, or nano-
sensors sensitive to more than one analyte, can be fabricated
which possess high signal to noise ratios. Typically, fluores-
cent nanosensors consist of two types of fluorophore, an indi-
cator and a reference. The indicator functions as a transducer,
which produces a signal corresponding to the concentration of
the analyte of interest. In contrast, the reference fluorophore is
insensitive to changes in analyte concentration, producing
a constant signal at a wavelength different to the indicator
FIG. 4. Schematic diagrams of nanosensors. (a) Sensor surfaces can be chemically tailored to enhance sensing capabilities or to augment cellular delivery. (b)
The reference dye is always active allowing for the nanosensors to be spatially located. (c) In the presence of the analyte of interest, activation occurs, and
both the reference and the sensory dye are active allowing measurements to be acquired.
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fluorophore. Therefore, incorporation of indicator fluorophores
and reference fluorophores in a nanosensor matrix permits
accurate ratiometric measurements to be made from a single
spatial coordinate. Similarly, if more than one indicator fluoro-
phore is incorporated into the matrix; fluorescent nanosensors
could be used to make simultaneous measurements of multiple
analytes of interest.
There are a diverse range of available fluorescent sensing
elements available for use. Similarly, there are many potential
matrices in which to encapsulate and protect these sensory
elements. This wide availability has provided fertile ground
for development of fluorescent nanosensors by a number of
research groups around the world. Fluorescent sensors have
been developed for physical properties such as tempera-
ture,57–60 biological molecules such as proteins,61,62 nucleic
acids63 and adenosine triphosphate,64,65 as well as a large
number of chemical entities including magnesium,43 mer-
cury,66 potassium,67 reactive oxygen species,68,69 sodium,70,71
zinc,72 calcium,73,74 copper,75 chloride,76 glucose,77 iron,78
lead,79 hydrogen ions (pH),54,80–82 and molecular
oxygen.83–85
D. Complex molecule sensors
Complex molecule sensors (CMSs) or affinity sensors are
similar to immunocytochemistry type assays in their ability
to detect specific molecules. CMS systems rely on specific
molecules able to bind both reversibly and specifically to the
analyte of interest.86 The major advantage for CMSs is that
they allow continuous monitoring of biomolecules rather
than one-off, end-point insights into a process. This is due to
the fact that CMSs, unlike antibody based immunocyto-
chemistry, bind reversibly to the molecule of interest and
thus can be reused.
A good example of a class of CMSs are fluorescence
resonance energy transfer (FRET) based sensing elements,
which are usually composed of an analyte sensitive macro-
molecule, such as a proteins or nucleic acids (e.g., aptamers),
that are conjugated to two different fluorophores. The pri-
mary fluorophore acts as a FRET donor that emits fluores-
cence at a wavelength which excites fluorescence in a
secondary fluorophore, a FRET acceptor. When the macro-
molecule senses an analyte of interest it undergoes a confor-
mational change which can bring together or separate the two
fluorophores. When the two fluorophores are extremely close
together, typically with a F€orster distance of less than 10 nm,
the primary fluorophore excites the secondary fluorophore to
express fluorescence that can be quantified. The combination
of the two fluorophores in this manner makes FRET based
sensors intrinsically ratiometric. Zhang and Wang have
reported nanosensors that utilize cadmium-selenide-zinc sul-
fide (CdSe-ZnS) quantum dots and Cy5, which function as a
FRET donor and acceptor, respectively, over a F€orster dis-
tance of 69.4 A˚ (or 6.94 nm), to sense low concentrations of
nucleic acids.87 For further information regarding quantum
dot based nanosensors for molecular sensing in biological
systems please refer to an in depth review by Zhang et al.88
III. DISCUSSION
There is considerable potential for emerging fluorescence
optical sensory probes to contribute to process control of
CGT factories of the future. In order to facilitate these
changes sensory systems that accurately detect and allow
subsequent control of population heterogeneity and quality
must ultimately be selected from the scientific advances and
translated to commercial scale.89
For fluorescent optical sensors, in particular, fluorescent
nanosensors, to acquire broad utility as a medical diagnostic
tools it is important that their signals can be accurately
obtained from thick and turbid samples, such as tissue and
organs. Currently, it is challenging to obtain fluorescent sig-
nals at depths using high powered objective lenses, due to
their short working distance, while turbid samples are known
to scatter light such that accurate signal reconstruction is
challenging. Ruan et al. have attempted to overcome some
of these challenges by using pulsed ultrasound to modulate
the scattered light from thick and turbid samples. However,
at present, this approach is unable to reach the resolutions of
conventional fluorescence microscopy.90 Nevertheless, when
fluorescence microscopy is combined with powerful tools
such as fluorescent nanosensors, vast amounts of information
can still be derived from individual cells that are thin and
optically transparent.
Optical microscopy, in particular, fluorescence micros-
copy, has elucidated a vast amount of detail about the inner
workings of cells. This is largely due to the high spatial and
temporal resolution of fluorescence microscopy as a detec-
tion technique and the high sensitivity of probes that can be
delivered to cells in a noninvasive manner. High numerical
aperture objective lenses and conventional charged couple
device or complementary metal–oxide–semiconductor cam-
eras have a diffraction limit of approximately 200 nm. With
the introduction of super-resolution fluorescence based tech-
niques, this spatial and temporal resolution has further
improved permitting the tracking of single molecules in bio-
logical systems.
Optical techniques will always be limited by distance
from the detector. Thus, in order to contribute to highly scal-
able culture environments, optical techniques can benefit
from fluorescent probe sensors that are able to provide
insight from distances far removed from the detector, if
implemented effectively. For example, real-time measure-
ment of key biomanufacturing parameters from fluorescent
nanosensors embedded within a packed bed bioreactor,
could be considered as a method to overcome the limitations
of traditional probe based sensors.
IV. CONCLUSION
The use of electrodes for determining culture environments
is still common practice. Although, scalable CGT manufacture
has evolved, it has become clear that there is an ever-
increasing gulf between the process biology requiring observa-
tion and the technology available to study it. Chemical based
optical sensors offer an exciting measurement solution to meet
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these current challenges in acquisition. When compared
to existing offline methods, the data these physiochemical sen-
sors make available may seem limited. However, the ability to
collect in real-time culture metrics beyond those typically
available with electrode-based technology is a major step for-
ward that will facilitate increasingly efficient processes with a
greater degree of control and provenance.
For emerging CGTs, this advance in measurement tech-
nologies offers a significant insight into the complex meta-
bolic processes that ultimately define the CQAs of the
product. The key to unlocking these bioprocessing advances
will be responsive and sensitive biosensors that are able to
detect increasingly complex process parameters in efficient
and scalable CGT manufacturing environments. To this end,
strategies for translating lab-scale sensory technologies to
production-scale should be pursued.
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